264 related articles for article (PubMed ID: 23900425)
1. Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen.
Kim SH; Jung DI; Yang IY; Jang SH; Kim J; Truong TT; Pham TV; Truong NU; Lee KY; Jang YS
Int Immunol; 2013 Nov; 25(11):623-32. PubMed ID: 23900425
[TBL] [Abstract][Full Text] [Related]
2. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization.
Kim SH; Yang IY; Jang SH; Kim J; Truong TT; Van Pham T; Truong NU; Lee KY; Jang YS
Microbes Infect; 2013 Nov; 15(13):895-902. PubMed ID: 23892099
[TBL] [Abstract][Full Text] [Related]
3. Expression and characterization of an M cell-specific ligand-fused dengue virus tetravalent epitope using Saccharomyces cerevisiae.
Nguyen NL; So KK; Kim JM; Kim SH; Jang YS; Yang MS; Kim DH
J Biosci Bioeng; 2015 Jan; 119(1):19-27. PubMed ID: 25027708
[TBL] [Abstract][Full Text] [Related]
4. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination.
Kim SH; Seo KW; Kim J; Lee KY; Jang YS
J Immunol; 2010 Nov; 185(10):5787-95. PubMed ID: 20952686
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate.
Bal J; Jung HY; Nguyen LN; Park J; Jang YS; Kim DH
Microb Cell Fact; 2018 Sep; 17(1):146. PubMed ID: 30217208
[TBL] [Abstract][Full Text] [Related]
6. C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-γ-producing T-cell responses in a mucosal dengue vaccine model.
Kim SH; Kim YN; Kim J; Jang YS
Cell Immunol; 2018 Mar; 325():41-47. PubMed ID: 29397905
[TBL] [Abstract][Full Text] [Related]
7. Immune Responses to Orally Administered Recombinant
Zhang F; Zhang Z; Li X; Li J; Lv J; Ma Z; Pan L
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696469
[TBL] [Abstract][Full Text] [Related]
8. Oral immunization with a Lactobacillus casei-based anti-porcine epidemic diarrhoea virus (PEDV) vaccine expressing microfold cell-targeting peptide Co1 fused with the COE antigen of PEDV.
Wang XN; Wang L; Zheng DZ; Chen S; Shi W; Qiao XY; Jiang YP; Tang LJ; Xu YG; Li YJ
J Appl Microbiol; 2018 Feb; 124(2):368-378. PubMed ID: 29178509
[TBL] [Abstract][Full Text] [Related]
9. Oral Delivery of Probiotics Expressing Dendritic Cell-Targeting Peptide Fused with Porcine Epidemic Diarrhea Virus COE Antigen: A Promising Vaccine Strategy against PEDV.
Wang X; Wang L; Huang X; Ma S; Yu M; Shi W; Qiao X; Tang L; Xu Y; Li Y
Viruses; 2017 Oct; 9(11):. PubMed ID: 29068402
[TBL] [Abstract][Full Text] [Related]
10. Roles of M cells in infection and mucosal vaccines.
Wang M; Gao Z; Zhang Z; Pan L; Zhang Y
Hum Vaccin Immunother; 2014; 10(12):3544-51. PubMed ID: 25483705
[TBL] [Abstract][Full Text] [Related]
11. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
12. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
[TBL] [Abstract][Full Text] [Related]
13. Systemic and mucosal immunity induced by attenuated Salmonella enterica serovar Typhimurium expressing ORF7 of porcine reproductive and respiratory syndrome virus.
Han YW; Kim SB; Rahman M; Uyangaa E; Lee BM; Kim JH; Park KI; Hong JT; Han SB; Eo SK
Comp Immunol Microbiol Infect Dis; 2011 Jul; 34(4):335-45. PubMed ID: 21543119
[TBL] [Abstract][Full Text] [Related]
14. Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination.
Nantachit N; Sunintaboon P; Ubol S
Virol J; 2016 Aug; 13():142. PubMed ID: 27538960
[TBL] [Abstract][Full Text] [Related]
15. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a neutralizing epitope from porcine epidemic diarrhea virus: M cell targeting ligand fusion protein expressed in transgenic rice calli.
Huy NX; Kim SH; Yang MS; Kim TG
Plant Cell Rep; 2012 Oct; 31(10):1933-42. PubMed ID: 22736145
[TBL] [Abstract][Full Text] [Related]
17. Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines.
Kim SH; Jang YS
Exp Mol Med; 2014 Mar; 46(3):e85. PubMed ID: 24626171
[TBL] [Abstract][Full Text] [Related]
18. Targeted Delivery of VP1 Antigen of Foot-and-mouth Disease Virus to M Cells Enhances the Antigen-specific Systemic and Mucosal Immune Response.
Kim SH; Lee HY; Jang YS
Immune Netw; 2013 Aug; 13(4):157-62. PubMed ID: 24009543
[TBL] [Abstract][Full Text] [Related]
19. Inclusion bodies from recombinant bacteria as a novel system for delivery of vaccine antigen by the oral route.
Kesik M; Saczyńska V; Szewczyk B; Płucienniczak A
Immunol Lett; 2004 Feb; 91(2-3):197-204. PubMed ID: 15019290
[TBL] [Abstract][Full Text] [Related]
20. Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres.
Brandhonneur N; Loizel C; Chevanne F; Wakeley P; Jestin A; Le Potier MF; Le Corre P
Int J Pharm; 2009 May; 373(1-2):16-23. PubMed ID: 19429284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
